Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Recce Pharmaceuticals Ltd. ( (AU:RCE) ) has shared an update.
Recce Pharmaceuticals Ltd announced that its RECCE® 327 Topical Gel (R327G) has shown statistically significant positive efficacy against Methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa in rat infection models. The study demonstrated that R327G not only reduced bacterial load significantly but also accelerated wound healing compared to the standard antibiotic Soframycin. This development supports ongoing collaboration with the U.S. Department of Defense, including a US$2M grant and a Cooperative Research and Development Agreement with the US Army Medical Research Institute of Infectious Diseases. The results suggest that R327G could offer a more effective and convenient treatment option for burn wounds, potentially benefiting patients, clinicians, and healthcare economics.
More about Recce Pharmaceuticals Ltd.
Recce Pharmaceuticals Ltd is a leading developer in the pharmaceutical industry, specializing in a new class of synthetic anti-infectives. The company focuses on addressing antibiotic-resistant pathogens, which are a significant threat to human health.
Average Trading Volume: 152,542
Technical Sentiment Signal: Sell
Current Market Cap: A$108.4M
Find detailed analytics on RCE stock on TipRanks’ Stock Analysis page.